Publication of Cancellation of Entries for Kinds of Medical Devices from the Australian Register of Therapeutic Goods – Shuzi Australia Pty Ltd - 193081

Overview

The Therapeutic Goods (Medical Devices) Amendment Regulations 2013, published as C2013G00642, were introduced to amend the Therapeutic Goods Act 1989 (TGA) to address the issue of medical devices that no longer meet the definition of a therapeutic good due to changes in product information or promotional material. This legislative instrument, enacted by the Australian Government and gazetted on 23 April 2013, targets the problem of maintaining accurate and up-to-date listings in the Australian Register of Therapeutic Goods (ARTG). The policy objective is to ensure that only products that genuinely meet the definition of a medical device remain listed, thus safeguarding public health and maintaining the integrity of the regulatory framework. As a delegate of the Secretary to the Department of Health and Ageing, Rodolfo Ferrari announced the cancellation of the ARTG entry for a specific kind of medical device, a Stimulator manufactured by Skytyan Inc (USA) and sponsored by Shuzi Australia Pty Ltd, due to the removal of all therapeutic claims from the product information and promotional material, rendering the product ineligible as a medical device under the TGA. The cancellation took effect on 31 May 2013, reflecting the legislative intent to uphold rigorous standards and regulatory compliance within the medical device industry.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, including medical devices, and encompasses a wide range of entities and individuals involved in the production, distribution, and sale of these goods. Specifically, Section 41GP applies to the cancellation of entries for kinds of medical devices from the Australian Register of Therapeutic Goods (ARTG). This section is pertinent to sponsors and manufacturers of medical devices, such as Shuzi Australia Pty Ltd and Skytyan Inc in the provided example, who must ensure that their products comply with the regulatory standards. The geographic reach of this legislation is national, affecting all medical devices across Australia, and is enforced by the Department of Health and Ageing. Exclusions and exemptions are not explicitly stated in the provided text, but generally, the Act allows for certain medical devices to be exempt under specific conditions. The Act may also extend its application through subordinate instruments, which provide further details and specific requirements for the registration and cancellation processes.

Key Provisions

The legislation C2013G00642 under section 41GP of the Therapeutic Goods Act 1989 (the Act) provides for the cancellation of certain entries from the Australian Register of Therapeutic Goods (ARTG). This particular notice (paragraph 1) announces the cancellation of an entry for a specific kind of medical device, a Stimulator, from the ARTG. The entry in question, identified by ARTG number 193081, was sponsored by Shuzi Australia Pty Ltd and manufactured by Skytyan Inc, a United States-based company. The cancellation became effective on 31 May 2013, following its publication date of 23 April 2013. The reason for the cancellation, as stated, is that the product no longer meets the definition of a medical device because all therapeutic claims have been removed from the product information and promotional material, rendering the initial certifications under section 41DA of the Act incorrect. Under the Act, the entities involved, specifically the sponsor and the manufacturer, bear specific obligations and requirements. The sponsor, Shuzi Australia Pty Ltd, is responsible for ensuring that the product information and promotional material align with the criteria for listing on the ARTG. Any changes to the product's therapeutic claims must be promptly communicated and verified to maintain the product’s eligibility as a medical device. Similarly, the manufacturer, Skytyan Inc, must ensure that the product adheres to the regulatory standards and definitions stipulated by the Act. Both parties must ensure compliance with the Act’s requirements to avoid the necessity for ARTG entry cancellations. Failure to comply with the provisions of the Therapeutic Goods Act 1989 can lead to significant consequences. The Act includes provisions for both civil and criminal penalties for breaches. For instance, under section 41GA of the Act, an entity may face civil penalties for non-compliance, with maximum penalties stipulated to be substantial, reflecting the seriousness of the breaches. Additionally, criminal penalties may apply, especially if the non-compliance results in harm to individuals or poses a significant risk to public health and safety. These penalties serve as deterrents to ensure that all entities governed by the Act adhere strictly to its provisions and maintain the integrity of the ARTG.